Commercial-stage pharmaceutical company Bio-Thera Solutions Ltd (SH:688177) announced on Thursday that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25.

The multicentre, open-label Phase 1 clinical trial in patients with advanced solid tumours aims to evaluate the safety and tolerability of BAT8013 and determine the recommended Phase 2 dose.

Preclinical studies have shown that BAT8013 has good stability and safety and has high anti-tumour activity in combination with Bio-Thera's PD-1 inhibitor, BAT1308.

Bio-Thera is also developing several additional ADCs targeting Folate Receptor alpha, Trop2 and Her2 along with additional innovative oncology assets directed at important IO targets, including novel bispecific targeting PD-L1/4-1BB and PD1/IL15, all in early-stage clinical studies.